Saturday 17 October 2026
Export DMRA’s income statement to Excel — free account
Galecto, Inc.
DMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.0% and free cash flow fell 877.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.42
0.32
−1.71%
Follow DMRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.73 | 12.98 | 22.48 | 19.73 |
Net Debt/EBITDA |
2.41 | 1.28 | 17.30 | 15.45 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.15 | 0.97 | 0.70 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.97) | 0.42 | (0.60) | (0.36) | |
Cash per Share |
5.73 | 189.01 | 15.54 | 8.84 | |
Shareholders Equity per Share |
6.03 | 176.36 | 14.92 | 8.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.03 | 176.36 | 14.92 | 8.44 | |
Free Cash Flow |
(2.62) | 0.57 | (20.60) | (21.87) | |
Working Capital |
7.16 | 240.36 | 511.60 | 516.04 | |
Net Current Asset Value |
7.06 | 240.28 | 511.57 | 516.01 | |
| Other line items | |||||
Quick Ratio |
2.90 | 12.84 | 22.38 | 19.62 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.97) | 0.42 | (0.60) | (0.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.51 | 9.02 | 6.59 | 4.95 | |
Average Assets |
17.06 | 138.83 | 275.40 | 278.66 | |
Average Common Equity |
13.80 | (80.70) | 195.75 | 197.84 |
Columns are period end dates